Tenapanor Hydrochloride is an oral sodium/hydrogen exchanger 3 (NHE3) inhibitor and a novel phosphate lowering drug. The kidney, as a key organ regulating phosphate balance, cannot effectively excrete phosphate when its function is severely impaired, leading to hyperphosphatemia becoming a common problem in CKD patients, especially dialysis patients. Although phosphate binders are used for treatment, the blood phosphorus concentration of dialysis patients may still increase in the long term.Tenapanor as an NHE3 inhibitor, can reduce the intake of sodium in the intestine, create conditions that inhibit the tight junction of the gastrointestinal tract, reduce the absorption of phosphate, and thus lower blood phosphorus concentration.
CAS.NO 1234365-97-9
We can support intermediate,API and the technology transfer from starting material to api.Contact information:Mr.Xu19965424115.